News & Insights
Besides sharing our hands-on expertise in projects, we regularly share industry insights, updates, and news.
EIC Awards €2.5 Million Grant
Following a rigorous selection process by an expert panel, Trince, NecstGen, and IBSAL are proud to announce that their “Penphomet” project has been selected by The European Innovation Council (EIC) for a significant grant of €2.5 million.
Exploring the Impact of iPSC-Derived Organoids on Biomedical Science
Discover the role of iPSC-derived organoids in biomedical science, advancing our understanding of human biology and opening doors.
The Ethical Advantages of iPSCs
Stem cell research has long been mired in ethical controversies, primarily around embryonic stem cell use, which involves complex moral and philosophical debates. The advent of iPSCs presents a turning point, promising a less contentious path forward in regenerative medicine.
Webinar
Transforming Your LV Process for CAR T to a Scalable, GMP-Ready ProcessKey areas of focus include: Transitioning from research to clinical application presents numerous challenges, particularly for CAR T developers, academic institutions, and small companies at a...
Webinar Product Quality For Cell Therapies
This session is all about building and testing strategies to set the groundwork for effective development and testing in your own work.
NecstGen and Aarhus University Collaborate in Groundbreaking Initiative for GMP-Compliant Stem Cell Production
NecstGen, Netherlands, a pioneering biotechnology center and non-profit CDMO specialising in Gene and Cell therapy, is proud to announce its groundbreaking collaboration with the Center for Gene and Cellular Therapy at Aarhus University Hospital (AUH), Denmark.
What are iPSCs? And what is their potential?
What are iPSCs? And how can we harness induced Pluripotent Stem Cells’ potential for the betterment of patient care?
Webinar iPSC Banking & Derivation
iPSC Banking & Derivation Ever wondered how to transition from bench to GMP suitable processes in the iPSC-derived therapies field? Yes? Watch the webinar replay on iPSC Derivation & Banking.Key areas of focus include: Transitioning from Bench to GMP Suitable...
NecstGen and ProteoNic Report Development of Improved Viral Vectors Through the Application of Premium 2G UNicTM Technology
NecstGen and ProteoNic announce the successful development of improved lentiviral vectors for Cell and Gene Therapy, leveraging ProteoNic’s premium 2G UNic™ technology.
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
Cline Scientific announces Letter of Intent with NecstGen for the manufacture of its stem cell therapy for damaged cartilage
bioMérieux partners with NecstGen
bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
NecstGen Announces Major Milestone – GMP Manufacturing License
The NecstGen team is happy to announce that is has received its GMP Manufacturing License.
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development
Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development.
Webinar: How to develop your Cell Therapy manufacturing process
How do you translate your Cell Therapy processes to GMP? What are the challenges of bringing an iPSC-based therapy to the patient? How to set up a CAR-T manufacturing process?
Press Release Horizon Europe Grant BioProS
As part of the Horizon Europe framework, NecstGen has joined an international consortium, that will work to develop Biointelligent Sensors for real time in production measurement and control of therapeutics including Cell and Gene Therapies.
European Cell and Gene Therapy companies
European Cell & Gene Therapy CompaniesAt NecstGen, we aim to support industry partnerships and growth. And to enable the next generation of therapies, it is pivotal to have oversight of the gene and therapy landscape to start from, which is why we created this...
Press Release Opening NecstGen
NecstGen announces the opening of its Cell and Gene Therapy Manufacturing and Development facility. On 1 June 2022, NecstGen’s brand-new GMP manufacturing and development facility for cell and gene therapies has been opened by Henri Lenferink (Mayor of Leiden), in the...
ProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene Therapies
Leiden, Netherlands, April 26, 2022 - ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, and NecstGen, a CDMO and centre of excellence for Cell and Gene Therapy, announce a partnership for the development of...
Outsourcing Cell & Gene Therapy Manufacturing
Outsourcing Cell Therapy Manufacturing Questions to ask yourselfCell and Gene therapies include extracting cells or genetic material (DNA) from a patient, altering that material to develop a highly personalized therapy and subsequently injecting it back into the...
NecstGen participates in € 300 million stem cell consortium
Today, the Novo Nordisk Foundation announced the € 300 million funding of an international consortium including Leiden University Medical Center, the Danstem Institute at the University of Copenhagen and the Murdoch Childrens Research Institute in Melbourne to bring...
Strategic collaboration with Cytiva
Today, NecstGen announces the strategic collaboration with Cytiva, a solutions provider in life sciences. Cytiva offers, among others, specialized expertise in industrial manufacturing of Cell and Gene Therapies. Together, NecstGen and Cytiva will share knowledge,...
NecstGen launches its first development lab
We are happy to announce the launch of NecstGen’s first development laboratory at the Leiden Bio Science Park. Here, our scientists and analytical experts have started the first process development projects, supporting our clients to bring cell- and viral vector-based...
Johan Hyllner joins strategic advisory board of NecstGen
NecstGen announces the addition of Johan Hyllner to its strategic advisory board. Johan Hyllner is leading expert in cell therapy and enabling technologies. He is professor of engineering biology at Linköping University, Sweden and head of the Cell Therapy...
NecstGen contracts Kuijpers for the construction of its Cell and Gene Therapy facility
NecstGen announces that the Dutch constructor Kuijpers has obtained the contract for the construction of its Cell- and Gene Therapy facility. Throughout the next year, NecstGen’s facility will be constructed in Mirai House on the largest Life Science and Health hub of...
NecstGen obtains €2 Million from Province South Holland
Today, Meindert Stolk, deputy Economy and Innovation of the Province South Holland visited NecstGen to hand over a symbolic cheque of € 2 million to Paul Bilars, CEO of NecstGen. Throughout the last years, the province has been closely involved with developments at...
56 million euro from Dutch ‘Groeifonds’ to pilot factory for regenerative therapies
Today, the Dutch cabinet announced the investment of €56 million into the establishment of a “pilot factory” for regenerative therapies. NecstGen and three other facilities will form a chain covering the development and manufacturing of cell therapies, biomaterials,...
Markwin Velder joins strategic board of NecstGen
NECSTGEN announces the addition of Markwin Velders to its strategic advisory board. Markwin Velders brings almost 20 years of experience as entrepreneur in the field of cell and gene therapy. He is Chairman of HollandBIO and co-founder of various biotech companies. As...
Sander van Deventer joins strategic advisory board of NecstGen
NECSTGEN announces the appointment of Sander van Deventer to its strategic advisory board. Sander van Deventer adds both scientific as well as commercial expertise in the field of cell and gene therapy. He is professor of Translational gastroenterology at the Leiden...
NecstGen Teams up with IT-partner LINKIT
NECSTGEN has started a collaboration with IT-partner LINKIT. NECSTGEN is a spin out of the Leiden University Medical Center that will support clinicians, academic groups and small industrial therapy developers globally to bring cell and gene therapies to patients....
Launch of NecstGen in Leiden, The Netherlands
We are happy to announce the official launch of the Netherlands Center for the Clinical Advancement of Stem Cell & Gene Therapies (NECSTGEN). The new center has been established to accelerate the development and clinical realization of cell and gene therapies....
